The contract is valued at up to $24m for the upcoming two years.
The company expects to facilitate the development of Rx100, a radiomitigant countermeasure drug used against lethal effects of radiation.
Rx100 has demonstrated survival benefit when administered either 24 hours before or up to 72 hours after exposure to lethal radiation levels.
RxBio chairman and CEO McCool said the radiation countermeasure would help save the lives numerous individuals who are exposed to lethal levels of radiation.